Oncoptpeptides - Bring hope through science

Bringing hope through science

Webcast - OCEAN topline results

Oncopeptides presented positive topline results from the phase 3 OCEAN and hosted a webcast May 25, 2021, at 11:00 (CET). 

The webcast included presentations by CEO Marty J Duvall, CSO Jakob Lindberg, CMO Klaas Bakker and Anders Martin-Löf CFO. The webcast was recorded.

More info, presentation and the webcast link

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions. 
Read more

Released

Interim report Q1 2021

”A strong start for PEPAXTO in the US”

CEO Marty J Duvall

 

See the Webcast


For further information, please contact:

Linda Holmström
Director of Investor Relations

Profile image
Events Oncopeptides

Upcoming events

View calendar

Released

Annual Report 2020

“The past year was a transformational year for Oncopeptides  highlighted by the FDA´s priority review of our NDA submission, which paved the way for an accelerated approval in the U.S. in early 2021.”

Marty J Duvall, CEO

 

Click here to watch the film where CEO Marty J Duvall summarizes a transformational year.

 

Annual Report 2020 - online version

 

For further information, please contact:

Linda Holmström
Director of Investor Relations

Profile image
Oncopeptides vision

Vision of Oncopeptides

“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Webinar Embassy of Sweden

Seminar at the Embassy of Sweden Washington DC

The Embassy of Sweden in Washington DC, Oncopeptides AB, Dana Farber and Uppsala University hosted a virtual seminar on February 2nd,“A Swedish American Journey of Cancer Research”. 

Read more

Cultures & Values

We are science and data driven, innovative and curious, making decisions based on systematic and thorough analyses.

Read more